LENZ Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LENZ research report →
Companywww.lenz-tx.com
LENZ Therapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
- CEO
- Evert Schimmelpennink
- IPO
- 2024
- Employees
- 6
- HQ
- Solana Beach, CA, US
Price Chart
Valuation
- Market Cap
- $225.75M
- P/E
- -2.07
- P/S
- 10.76
- P/B
- 0.92
- EV/EBITDA
- -1.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.16%
- Op Margin
- -563.83%
- Net Margin
- -519.30%
- ROE
- -46.82%
- ROIC
- -47.96%
Growth & Income
- Revenue
- $19.09M · 0.00%
- Net Income
- $-82,127,000 · -65.02%
- EPS
- $-2.85 · -21.79%
- Op Income
- $-91,138,000
- FCF YoY
- -16.94%
Performance & Tape
- 52W High
- $50.40
- 52W Low
- $6.61
- 50D MA
- $9.62
- 200D MA
- $23.19
- Beta
- 1.67
- Avg Volume
- 943.46K
Get TickerSpark's AI analysis on LENZ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 27, 26 | George Jeffrey P. | buy | 5,592 |
| Mar 27, 26 | Schimmelpennink Evert B. | buy | 28,089 |
| Mar 27, 26 | Chevallard Daniel R. | buy | 7,500 |
| Jan 2, 26 | Olsson Shawn | other | 84,200 |
| Jan 2, 26 | Olsson Shawn | other | 14,000 |
| Jan 2, 26 | Odrich Marc | other | 84,200 |
| Jan 2, 26 | Odrich Marc | other | 14,000 |
| Jan 2, 26 | Chevallard Daniel R. | other | 84,200 |
| Jan 2, 26 | Chevallard Daniel R. | other | 14,000 |
| Jan 2, 26 | Schimmelpennink Evert B. | other | 358,100 |
Our LENZ Coverage
We haven't published any research on LENZ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LENZ Report →